Global Fabry Disease
Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016 – 2026
Future Market Insights
www.futuremarketinsights.com
[email protected]
Report
Description
Report Description
Fabry disease is also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is
a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alphagalactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in
the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease
is known to cause variety of systemic symptoms and complications, one of them being metabolic
disorders. The metabolism of sphingolipids is minimized, in fabry disease which results in the
multiple organ failure and death. Owing to the deficiency of alpha galactosidase A enzyme,
glycolipid called Gb3 accumulates in the blood vessels and other organs and thus results in
formation of blockage or clots that leads to malfunctioning of the system.
Fabry Disease Market: Drivers and Restraints
The major drivers that drive the fabry disease market growth are extensive R&D activities,
adoption of advanced technologies in the research practices. Due to hereditary nature and
severity of the disease, complications in physiological systems, such as cardiac system, urinary
system and others are expected to increase the demand for trustworthy treatment. Extensive
R&D practices is one of the valuable drivers of the market. Due to this, various therapeutic
products, such as, PRX-102, JR-051, NP-003, GC-1119 and others, are under pipeline studies.
However, rare incidence rate (1 in 40,000), lack of awareness about advancements in genetic
sciences, technological limitations in certain region of the world are some of the restraining
factors that may affect the growth of the fabry disease market.
Report
Description
Report Description
Fabry Disease Market: Segmentation
The global fabry disease market has been classified on the basis of treatment, end use and
geography.
Based on treatment, the global fabry disease market is divided into following:
• Enzyme replacement therapy
• Gene therapy
• Pharmaceutical formulations containing agalsidase alpha
• Analgesics
• Anticonvulsants
• NSAIDs
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb1365
Based on end user type, the global fabry disease market is divided into following:
• Hospitals
• Clinics
Fabry Disease Market: Overview
The enzyme replacement therapy is designed to provide enzyme to the patients suffering from
enzyme deficiency. It was found that this treatment was not a complete cure though it improved
Report
Description
Report Description
the metabolism. Enzyme replacement therapy is the most expensive and unaffordable
treatment among the treatments for fabry disease, hence the market for enzyme replacement
therapy is expected to register moderate growth in overall fabry disease market. The analgesics,
anticonvulsants and NSAIDs are generally known for the treatment of pain and other symptoms
associated with fabry disease hence, contributing majorly to the market.
Visit For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1365
Fabry Disease Market: Regional Overview
Geographically, the global fabry disease market is classified into regions namely, North America,
Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa. North
America is estimated to be the most lucrative region owing to the affordability of the treatment
followed by Europe. The rare incidences in APAC and MEA countries are expected to limit the
growth of fabry disease market in these regions.
Fabry Disease Market: Key Players
The major players operating in this market and involved in development of new medications
include Sanofi-Aventis LLC, iBio, Inc., GlaxoSmithKline plc, Genzyme Corporation, and Neuraltus
Pharmaceuticals, Inc. Some of the existing key players in the global fabry disease market are
Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Amgen
Inc., Teva pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd.
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research
Capabilities




Customized Research
Syndicated Research
Investment Research
Social Media Research
Sector Coverage





Automotive and Transportation

Electronics, Semiconductor, and ICT

Retail and Consumer Products

Industrial Automation and Equipment

Healthcare, Pharmaceuticals & Medical Devices
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]
Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and
Gas
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
For other queries contact:
Future Market Insights 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705